Ke Ding, Ph.D

Affiliations: 
1991-1998 China Pharmaceutical University 
 1998-2001 Fudan university, Shanghai, Shanghai Shi, China 
 2006-2016 Guangzhou Institutes Biomedicine and Health,CAS 
 2016- Jinan University 
Google:
"Ke Ding"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zhang H, Lin G, Jia S, et al. (2024) Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors. Bioorganic Chemistry. 148: 107456
Liu L, Zhao L, Yang L, et al. (2024) Discovery of as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1. Journal of Medicinal Chemistry
Li H, Ke R, Zhou Y, et al. (2024) Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor. European Journal of Medicinal Chemistry. 272: 116473
Liu L, Parolia A, Liu Y, et al. (2024) Discovery of LLC0424 as a Potent and Selective NSD2 PROTAC Degrader. Journal of Medicinal Chemistry
Niu P, Tao Y, Lin G, et al. (2024) Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. Journal of Medicinal Chemistry
Niu P, Tao Y, Meng Q, et al. (2024) Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors. Bioorganic & Medicinal Chemistry. 104: 117711
Zhu Z, Li J, Shen S, et al. (2024) Targeting EGFR degradation by autophagosome degraders. European Journal of Medicinal Chemistry. 270: 116345
Qiu X, Liu R, Ling H, et al. (2024) Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors. European Journal of Medicinal Chemistry. 269: 116310
Sun Y, Chen Z, Liu G, et al. (2023) Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor. Bioorganic Chemistry. 143: 107053
Liu W, Bai Y, Zhou L, et al. (2023) Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia. European Journal of Medicinal Chemistry. 264: 115974
See more...